32,942 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by RPg Family Wealth Advisory LLC

RPg Family Wealth Advisory LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 32,942 shares of the biopharmaceutical company’s stock, valued at approximately $1,886,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after acquiring an additional 856,200 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $23,211,000. Swedbank AB bought a new stake in Halozyme Therapeutics in the first quarter valued at about $13,927,000. Finally, Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 0.1 %

Shares of NASDAQ:HALO opened at $47.76 on Wednesday. The company has a 50 day moving average of $54.00 and a 200-day moving average of $53.71. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The stock has a market cap of $6.08 billion, a price-to-earnings ratio of 15.82, a P/E/G ratio of 0.43 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Benchmark reaffirmed a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JMP Securities boosted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders sold 60,000 shares of company stock valued at $3,425,000. Company insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.